Lunit (328130.KQ) will present five research abstracts using its Lunit SCOPE AI biomarker platform at the European Society for Medical Oncology (ESMO) 2026 congress in Madrid, Spain, from Oct. 23 to 27. The studies cover non-small cell and small cell lung cancer, breast cancer and pancreatic ductal adenocarcinoma, examining treatment biomarkers, tumor biology and prognosis. One study assesses agreement between Lunit SCOPE and pathologists in evaluating PD-L1 expression in surgical specimens from Japanese non-small cell lung cancer patients. Another compares AI algorithms for HER2 analysis through the French cancer center ICO's AIforHER project. Additional research examines endothelial cells, KRAS mutation subtypes and tertiary lymphoid structures in relation to patient outcomes. Lunit will operate an exclusive booth with live demonstrations of its pathology-image analysis products. The company said ESMO attracts more than 30,000 people annually, and Lunit has participated for six consecutive years since its first appearance in 2021.